A practical reference on freeze-thaw: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common supplier description |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water |
| Typical storage | −20 °C, desiccated, dark | For research samples |
| Analytical method | LC-MS/MS | Used for detection and quantification |
| Regulatory status | Prohibited in sport | WADA metabolic modulator class |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
The Jardin des Vestiges (Occitan: Jardin dels Vesticis) is a garden containing the archaeological remains of the ancient port of Marseille, France. The site is located in the 1st arrondissement, behind the shopping arcade in the Centre Bourse. Classified as a French historical monument, it was excavated archaeologically in 1967 and officially opened on 17 October 2009. The site was part of the ancient Greek city of Massalia. It includes parts of the ancient port and city walls, with remains of three square towers and a gateway dating back to the second or third century BC.
== Interactions == The effect of the interfacial layer is clearly seen in the interactions between nanoparticles. These interactions can be modelled using the DLVO theory. Classically this theory states that the potential of a particle is the sum of the electrostatic and van der Waals interaction. This is theory has proven to be very accurate for almost all Colloidal particles, but cannot describe all the interactions measured for nanoparticles. Therefore this theory has been extended with the so called non-DLVO terms. In this extension the hydration force, hydrofobic force, steric force and bridging force are also considered, resulting in a total potential as follows:
E-liquids were purchased from retailers and via online for a 2013 study. The Royal College of General Practitioners stated in 2016 that "To date 42 chemicals have been detected in ENDS aerosol – though with the ENDS market being unregulated there is significant variation between devices and brands." E-liquid nicotine concentrations vary. The amount of nicotine stated on the labels of e-liquids can be very different from analyzed samples. Some e-liquids sold as nicotine-free contained nicotine, and some of them were at substantial levels. The analyzed liquids nicotine levels were between 14.8 and 87.2 mg/mL and the actual amount varied from the stated amount by as much as 50%. Possibly, 60–70% of the nicotine is vaporized. E-cigarettes without nicotine is also available. Via nicotine-containing e-cigarettes, nicotine is absorbed through the upper and lower respiratory tract. A greater amount of nicotine is possibly absorbed through oral mucosa and upper airways. The composition of the e-liquid may affect nicotine delivery. E-liquid containing glycerin and propylene glycol delivers nicotine more efficiently than a glycerin-based liquid with the same amount of nicotine. It is believed that propylene glycol vaporizes quicker than glycerin, which subsequently transports a higher amount of nicotine to the user. Vaping appears to give less nicotine per puff than cigarette smoking.
Sources: en.wikipedia.org
Dermatology Neurosurgery Ophthalmology Oral and maxillofacial surgery Orthopedic surgery Otorhinolaryngology Podiatric surgery – do not undergo medical school training, but rather separate training in podiatry school Urology
Dextromethorphan (the stereoisomer of levomethorphan, a semi-synthetic opioid agonist) and its metabolite dextrorphan have no opioid analgesic effect at all despite their structural similarity to other opioids; instead they are potent NMDA antagonists and sigma 1 and 2-receptor agonists and are used in many over-the-counter cough suppressants. Salvinorin A is a selective, powerful ĸ-opioid receptor agonist. It is not considered an opioid nevertheless, because:
=== Names === Selegiline is the generic name of the drug and its INNTooltip International Nonproprietary Name, BANTooltip British Approved Name, and DCFTooltip Dénomination Commune Française, while selegiline hydrochloride is the USANTooltip United States Adopted Name. The word "selegiline" is pronounced (sə-LEJ-i-leen) or as "seh-LEH-ji-leen". Selegiline is also known as L-deprenyl, L-deprenil, L-deprenalin, L-deprenaline, L-phenylisopropylmethylpropinylamine, and L-E-250. It should not be confused with the racemic form, deprenyl (E-250), or with the dextrorotatory enantiomer, D-deprenyl, which are distinct substances. Major brand names of selegiline include Eldepryl, Jumex, and Movergan (oral tablet and/or capsule), Zelapar (orally disintegrating tablet or ODT), and Emsam (transdermal patch). Selegiline has been marketed under more than 70 brand names worldwide. The brand name "Emsam" was derived from the names of two children, Emily and Samuel, of one of the executives at Somerset Pharmaceuticals, the developer of Emsam.
Sources: en.wikipedia.org
David Hasselhoff as S.H.I.E.L.D. Agent Colonel Nick Fury Lisa Rinna as S.H.I.E.L.D. Agent Contessa Valentina "Val" Allegra De Fontaine Sandra Hess as Andrea Von Strucker/Viper Neil Roberts as S.H.I.E.L.D. Agent Alexander Pierce Garry Chalk as S.H.I.E.L.D. Agent Timothy Aloysius "Dum-Dum" Dugan Tracy Waterhouse as S.H.I.E.L.D. Agent Kate Neville Tom McBeath as S.H.I.E.L.D. Director General Jack Pincer Ron Canada as S.H.I.E.L.D. Agent Gabriel Jones Adrian G. Griffiths as S.H.I.E.L.D. Agent Clay Quartermain Peter Haworth as Dr. Arnim Zola Campbell Lane as Baron Wolfgang Von Strucker Scott Heindl as Werner Von Strucker Mina E. Mina as H.Y.D.R.A. Cairo Lieutenant Stellina Rusich as Inspector Gail Runciter Rick Ravanello as S.H.I.E.L.D. Agent J. Vaughn Roger Cross as S.H.I.E.L.D. Agent #1 Bill Croft as H.Y.D.R.A. Agent Garotte Terry David Mulligan as U.S. President
Acetylcysteine was patented in 1960 as a mucolytic agent. In the 1960s, it was used for managing the mucous symptoms of illnesses including cystic fibrosis, asthma, and chronic bronchitis, as well as other uses, such as a chelating agent in gold therapy. In the late 1960s, the popularity of acetaminophen led to an increase in overdose hepatotoxicity. In 1974, it was discovered that the mechanism was oxidation via cytochrome P450, and administering glutathione-like reducing agents, such as IV cysteine, or oral methionine, were successful in preventing hepatotoxicity. In the US, the then-common formulation of NAC was not certified as pyrogen-free, and thus not approved for IV use. The producer, Mead Johnson, was unwilling to take the expense of certification. In 1977, there was the first case report of oral NAC preventing acetaminophen overdose hepatoxicity in the US. Meanwhile, in the UK, IV NAC (trade name, Parvolex) was found to be more effective and has less side effect than IV cysteamine (associated with a "general feeling of misery") or methionine. There was a dispute concerning whether the oral NAC and the IV NAC is more effective, with the conclusion reached in 1999, that they are roughly equally effective. Another producer finally obtained approval for the IV form of NAC (trade name, Acetadote) in the US in 2004. Amazon removed acetylcysteine for sale in the US in 2021, due to claims by the Food and Drug Administration (FDA) of it being classified as a drug rather than a supplement.
=== Special precautions === Benzodiazepines require special precaution if used in the elderly, during pregnancy, in children, in alcohol- or drug-dependent individuals, and in individuals with comorbid psychiatric disorders. Impairment of driving skills with a resultant increased risk of road traffic accidents is probably the most important adverse effect. This side-effect is not unique to flunitrazepam but also occurs with other hypnotic drugs. Flunitrazepam seems to have a particularly high risk of road traffic accidents compared to other hypnotic drugs. Extreme caution should be exercised by drivers after taking flunitrazepam.
Each module performs all the catalytic reactions necessary to incorporate a single amino acid onto the peptide chain. This is accomplished through the subdomains for adenylation (A), peptityl carrier protein (PCP), condensation (C), and depending on the amino acid position, an epimerization (E). The adenylation subdomain is used in activating the specific amino acid. Each module uses one molecule of the selected substrate amino acid with one molecule of ATP to give an aminoacyl adenylate enzyme complex and pyrophosphate. The activated amino acid can then be transferred to the enzyme bound 4'-phosphopantetheine of the carrier protein with the expulsion of AMP from the system. The carrier protein uses the 4'-phosphopantetheine prosthetic group for loading of the growing peptide and their monomer precursors. Elongation of the peptide chain is achieved through condensation of the upstream PCP onto an adjacent downstream PCP-bound monomer. Some domains have modification subdomains, such as the E subdomain seen in domains 1 and 4 in tyrocidine, which will generate the D-configured amino acid. On the final module is the TE domain used as a catalyst for cyclization or product release. The release of the product from the carrier protein is achieved through acylation of the active site serine of TE in which the decapeptide is transferred from the thiol ether to the serine residue. Deacylation can then occur through intramolecular cyclization or through hydrolysis to give the cyclic or linear product respectively (See figure 4).
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.
Detection commonly uses liquid chromatography–tandem mass spectrometry. This method can identify the compound in urine or blood at low concentrations.
Typical guidance is −20 °C, dry, and protected from light. Solutions should be aliquoted and limited freeze–thaw cycles should be used.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.